Astellas Receives CHMP Positive Opinion for Perioperative Padcev + Keytruda for Muscle-Invasive Bladder Cancer (MIBC)

Why It Matters

The approval would give cisplatin‑ineligible MIBC patients a curative‑intent immunotherapy option, expanding Astellas’ oncology portfolio and opening a sizable European market for combination regimens.

Key Takeaways

• CHMP recommends Padcev + Keytruda for cisplatin‑ineligible MIBC patients
• Trial showed 60% event‑free survival boost versus surgery alone
• Overall survival risk cut by half with the combination therapy
• Approval would apply across all 30 European Economic Area countries
• Strengthens Astellas’ position in bladder‑cancer immuno‑oncology market

Pulse Analysis

Bladder cancer remains one of the most lethal urologic malignancies, with muscle‑invasive disease accounting for the majority of deaths. Patients who cannot receive cisplatin—approximately 40% of the MIBC population due to renal impairment, hearing loss, or poor performance status—have historically faced limited perioperative options, relying on surgery alone or suboptimal chemotherapy regimens. The unmet clinical need has spurred interest in immunotherapy‑based strategies that can both shrink tumors before resection and eradicate microscopic disease afterward.

The CHMP’s positive opinion follows robust data from the pivotal KEYNOTE‑905/EV‑303 trial, which randomized cisplatin‑ineligible patients to three arms: surgery alone, neoadjuvant/adjuvant Keytruda alone, and the combination of Keytruda with Padcev. The combination arm achieved a 60% relative increase in event‑free survival and halved the risk of death compared with surgery, endpoints that satisfy both regulatory efficacy thresholds and oncologists’ expectations for meaningful benefit. By recommending the regimen for all 30 EEA states, the CHMP signals confidence in the trial’s design, safety profile, and the therapeutic synergy of an antibody‑drug conjugate with a PD‑1 inhibitor.

For Astellas, the endorsement could translate into a multi‑hundred‑million‑dollar revenue stream, given the prevalence of cisplatin‑ineligible MIBC in Europe and the high price points typical of novel immuno‑oncology combos. The decision also paves the way for parallel submissions in the United States, where the FDA has shown openness to accelerated pathways for bladder‑cancer immunotherapies. Beyond immediate commercial impact, the approval may catalyze further research into perioperative checkpoint‑inhibitor combinations, reinforcing Astellas’ strategic focus on precision oncology and expanding treatment options for a historically underserved patient cohort.